Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.15 USD
Change Today 0.00 / 0.00%
Volume 22.0K
ILIU On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

interleukin genetics inc (ILIU) Snapshot

Open
$0.15
Previous Close
$0.15
Day High
$0.15
Day Low
$0.15
52 Week High
01/13/15 - $0.46
52 Week Low
12/15/14 - $0.05
Market Cap
25.9M
Average Volume 10 Days
48.8K
EPS TTM
$-0.04
Shares Outstanding
172.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERLEUKIN GENETICS INC (ILIU)

Related News

No related news articles were found.

interleukin genetics inc (ILIU) Related Businessweek News

No Related Businessweek News Found

interleukin genetics inc (ILIU) Details

Interleukin Genetics, Inc. focuses on the development and commercialization of personalized health products that help individuals to improve and maintain their health through preventive measures in the United States. It offers PerioPredict, a genetic test to analyze genetic variations associated with inflammation and identify individuals with risk for periodontal disease. The company also provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand. It is also involved in the development of osteoarthritis genetic tests for adult joint diseases. The company markets its Inherent Health brand of genetic tests through its e-commerce Website and under contract with Amway and various regional weight management focused organizations; and PST tests directly to dentists and periodontists. Interleukin Genetics, Inc. has clinical research collaborations with Stanford University, the University of North Carolina, the Mayo Clinic, Brigham & Women’s Hospital, University of California, New York University Medical Center, University of Sheffield, Yonsei University Medical Center, Tongji Medical College, Tuft’s University Medical Center, and Geisinger Clinic for the research and development of genetic tests. The company was founded in 1986 and is headquartered in Waltham, Massachusetts.

interleukin genetics inc (ILIU) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $401.4K
Interim Chief Financial Officer
Total Annual Compensation: $66.9K
Chief Marketing Officer
Total Annual Compensation: $290.8K
Compensation as of Fiscal Year 2014.

interleukin genetics inc (ILIU) Key Developments

Interleukin Genetics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Interleukin Genetics, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. The company’s revenues for the quarter ended December 31, 2014, were $322,000, compared to $671,000 for the same period in 2013. This decrease is primarily attributable to less breakage revenue (deferred revenue recognized when, after the passage of time, test redemption is considered unlikely) and license fee income recognized in 2014 compared the same period in 2013. These decreases are largely due to the recognition in the quarter ended December 31, 2013 of breakage revenue from test kit sales made in the years ended December 31, 2009 and 2010, and of license fee income for the quarters ended June 30, September 30, and December 31, 2013, whereas breakage revenue and license fee income recognized in the quarter ended December 31, 2014 related to that quarter only. Net loss for the quarter ended December 31, 2014, was $1.6 million, or $0.01 per basic and diluted common share, compared to $1.9 million or $0.02 per basic and diluted common share for the same period in 2013. Loss from operations was $1,626,959 or $0.01 per basic and diluted share against $1,912,138 or $0.02 per basic and diluted share a year ago. Loss from continuing operations before income taxes was $1,637,783 against $1,903,985 a year ago. The company’s revenues for the year ended December 31, 2014, were $1.8 million, compared to $2.4 million for the year ended December 31, 2013. The change in total revenue is attributable to higher revenues in 2013 due to a promotion by Interleukin’s partner, Amway, resulting in a larger volume of pre-paid test kits returned for processing, partially offset by $309,348 of breakage revenue recognized in the year ended December 31, 2014, compared to $213,233 of breakage revenue recognized in the year ended December 31, 2013. In addition, Interleukin earned $150,923 of royalties for the year ended December 31, 2014, from its license agreement with ABGI, compared to $198,960 of royalties earned in the year ended December 31, 2013. The net loss for the year ended December 31, 2014, was $6.3 million, or $0.05 per basic and diluted common share, compared to a net loss of $7.1 million, or $0.08 per basic and diluted common share for 2013. Loss from operations was $6,329,399 or $0.05 per basic and diluted share against $6,598,526 or $0.08 per basic and diluted share a year ago. Loss from continuing operations before income taxes was $6,335,714 against $7,057,933 a year ago.

Interleukin Genetics, Inc. Auditor Raises 'Going Concern' Doubt

Interleukin Genetics, Inc. filed its 10-K on Mar 19, 2015 for the period ending Dec 31, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Interleukin Genetics, Inc., Q4 2014 Earnings Call, Mar 20, 2015

Interleukin Genetics, Inc., Q4 2014 Earnings Call, Mar 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.15 USD 0.00

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies
 

Industry Analysis

ILIU

Industry Average

Valuation ILIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit www.ilgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.